Our results show that the combined treatment with JNK-IN-8 and dasatinib exhibits a better therapeutic effect in prolonging the life of BCR-ABL+ B-ALL mice than that by either JNK inhibitor or dasatinib alone. This evidence concerns the gene ABL1 and precursor B-cell acute lymphoblastic leukemia.